Taysha Gene Therapies Inc. Watch

from 8-K 8 pages Taysha Gene Therapies, Inc. Stock Option Grant Notice

from 8-K 6 pages Taysha Gene Therapies, Inc. Rsu Award Grant Notice

from 8-K 31 pages Taysha Gene Therapies, Inc. 2023 Inducement Plan Adopted by the Board of Directors: December 15, 2023

from 8-K 38 pages Securities Purchase Agreement

from 10-Q 3 pages Taysha Gene Therapies, Inc. Non-Employee Director Compensation Policy

from 10-K 7 pages March 7, 2023 Ra Session II Dear Ra: This Letter Sets Forth the Substance of the Separation Agreement (The “Agreement”) That Taysha Gene Therapies, Inc. (“Taysha” or the “Company”) Is Offering to You to Aid in Your Employment Transition. 1

from 10-K 12 pages December 30, 2022 Sukumar Nagendran, M.D. Re: Offer of Employment Dear Sukumar: Taysha Gene Therapies, Inc. (The “Company”) Is Pleased to Offer You Employment in the Position of President and Head of Research and Development on the Terms and Conditions Set Forth in This Letter Agreement (The “Agreement”). 1

from 10-K 11 pages December 30, 2022 Sean Nolan Re: Offer of Employment Dear Sean: Taysha Gene Therapies, Inc. (The “Company”) Is Pleased to Offer You Employment in the Position of Chief Executive Officer (“CEO”) on the Terms and Conditions Set Forth in This Letter Agreement (The “Agreement”). 1

from 8-K/A 23 pages Registration Rights Agreement

from 8-K/A 32 pages Securities Purchase Agreement

from 8-K/A 18 pages Certain Information Has Been Excluded From This Agreement (Indicated by “[***]”) Because Taysha Gene Therapies, Inc. Has Determined Such Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Option Agreement

from 10-K 5 pages Taysha Gene Therapies, Inc. Amendment No. 1 to Sales Agreement

from 10-K 5 pages First Amendment to Lease Agreement

from 10-Q 62 pages Lease Agreement Between Pegasus Park, LLC, as Landlord, and Taysha Gene Therapies, Inc., as Tenant Dated January 8, 2021 3000 Pegasus Park Drive Dallas, Texas Basic Lease Information

from 10-K 47 pages Article 1 - Lease of Premises

from 10-K 8 pages 1.position. You Will Continue to Be Employed in the Position of Chief Medical Officer and Head of Research and Development for the Company, and Will Continue to Report to the Company’s Chief Executive Officer. You Will Continue to Work Full-Time. This Position Remains an Exempt Position, Which Means You Will Be Expected to Work the Company’s Normal Business Hours as Well as Additional Hours as Required by the Nature of Your Work Assignments, and You Will Not Be Eligible for Overtime Compensation. You Will Perform Duties and Responsibilities as May Be Assigned to You From Time to Time. You Agree to Devote Your Best Efforts to the Performance of Your Duties and to the Furtherance of the Company’s Interests. 2. Salary

from 10-K 6 pages September 24, 2020 2. Salary

from 10-K 40 pages License Agreement Dated as of October 29, 2020 by and Between Abeona Therapeutics Inc. and Taysha Gene Therapies, Inc

from 10-Q 8 pages Amended and Restated Executive Employment Agreement

from S-1/A 7 pages 1. Position. You Will Continue to Be Employed in the Position of [Title] for the Company, and Will Continue to Report to the Company’s [Title]. You Will Continue to Work Full-Time. This Position Remains an Exempt Position, Which Means You Will Be Expected to Work the Company’s Normal Business Hours as Well as Additional Hours as Required by the Nature of Your Work Assignments, and You Will Not Be Eligible for Overtime Compensation. You Will Perform Duties and Responsibilities as May Be Assigned to You From Time to Time. You Agree to Devote Your Best Efforts to the Performance of Your Duties and to the Furtherance of the Company’s Interests. 2. Salary